Industry Information

Clinical study of low dose urokinase combined with defibrase in the treatment of progressive cerebral infarction

Progressive stroke is one of the most difficult to treat in cerebral infarction. At present, low-molecular-weight heparin is the first-line anticoagulant drug at home and abroad. In domestic studies, low-molecular-weight heparin calcium was used as the control in the treatment of progressive cerebral infarction by low-dose urokinase combined with defibrase. The results showed that the total effective rate of the treatment group was higher than that of the control group, and there was no case of cerebral hemorrhage. It is concluded that the combination of low-dose urokinase with defibrase can achieve stable thrombolytic, defibrinolytic and anticoagulant effects, and the treatment effect of progressive cerebral infarction is significant, which is worthy of clinical promotion.